Markets:

Overview

News

Currencies

International

Treasuries

Axsome Therapeutics, Inc. - Common Stock (NQ:AXSM)

181.21 -1.73 (-0.95%)

Streaming Delayed Price Updated: 4:00 PM EST, Feb 13, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Axsome Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

17 18 Next >

2 Top Stocks I Wouldn't Hesitate to Invest $1,000 in Right Now ↗

July 24, 2025

Via The Motley Fool

Where Axsome Therapeutics Stands With Analysts ↗

July 03, 2025

Via Benzinga

FDA Pushes Pause On Axsome Fibromyalgia Drug, New Trial Required ↗

June 09, 2025

The FDA rejected Axsome's AXS-14 fibromyalgia, prompting a new trial and pushing the expected drug launch to 2028.

Via Benzinga

Demystifying Axsome Therapeutics: Insights From 11 Analyst Reviews ↗

June 09, 2025

Via Benzinga

Axsome Stock Slips Pre-Market After FDA Issues Refusal-To-File Letter: Retail’s Skeptical On Likelihood Of Year-End Profitability ↗

June 09, 2025

The regulator said that upon preliminary review, it found that the new drug application for AXS-14 was not sufficiently complete to permit a substantive review.

Via Stocktwits

Topics Stocks

Earnings Scheduled For May 5, 2025 ↗

May 05, 2025

Via Benzinga

Deep Dive Into Axsome Therapeutics Stock: Analyst Perspectives (28 Ratings) ↗

February 27, 2025

Via Benzinga

2 Soaring Stocks Wth More Upside Potential ↗

June 05, 2025

Via The Motley Fool

Why Is Teva Stock Trading Higher On Tuesday? ↗

May 27, 2025

Teva starts IND-enabling studies for BD9, a dual-target therapy for asthma and atopic dermatitis, under license from Biolojic Design.

Via Benzinga

3 High-Flying Stocks That Could Soar Even More ↗

May 24, 2025

Via The Motley Fool

Expert Outlook: Axsome Therapeutics Through The Eyes Of 16 Analysts ↗

May 22, 2025

Via Benzinga

Is Axsome Therapeutics Stock Worth the Risk? A Comprehensive Analysis ↗

May 14, 2025

Via The Motley Fool

Prediction: These 2 Stocks Will Outperform the Market in the Next Five Years ↗

May 12, 2025

Via The Motley Fool

3 Monster Stocks in the Making ↗

May 11, 2025

Via The Motley Fool

Axsome Therapeutics Clocks Around 60% Topline Growth In Q1 ↗

May 05, 2025

Axsome beat Q1 expectations with $121.5 million in revenue and strong Auvelity sales as it prepares Symbravo's U.S. launch and advances key drug programs.

Via Benzinga

Deep Dive Into Axsome Therapeutics Stock: Analyst Perspectives (28 Ratings) ↗

April 29, 2025

Via Benzinga

This Reddit Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday ↗

April 07, 2025

Via Benzinga

Stocks Edge Higher Despite Trade, Economic Jitters ↗

April 01, 2025

Stocks are modestly higher Tuesday afternoon, as Wall Street shakes off a sluggish open amid a new wave of economic data.

Via Talk Markets

Topics Stocks / Equities

Why Shares of Axsome Therapeutics Slumped Today ↗

April 01, 2025

Via The Motley Fool

Axsome Therapeutics Dives Again On Its Second Big Drug Failure In A Week ↗

April 01, 2025

The company posted mixed results for its depression treatment, noting it appears to work in a smaller patient group.

Via Investor's Business Daily

Axsome's Solriamfetol Fails Primary Goal In Depression Study But Shows Improvements In Associated Sleep Disorder ↗

April 01, 2025

Axsome's Phase 3 trial for solriamfetol in MDD did not meet its primary endpoint, but positive data in severe EDS patients supports plans for a new study in 2025.

Via Benzinga

Celanese To Rally Around 27%? Here Are 10 Top Analyst Forecasts For Thursday ↗

March 27, 2025

Via Benzinga

Breaking Down Axsome Therapeutics: 31 Analysts Share Their Views ↗

March 27, 2025

Via Benzinga

Why Pharma and Biotech Stocks Got Thrashed on Tuesday ↗

March 25, 2025

Via The Motley Fool

IBD 50's Axsome Therapeutics Dives On Mixed ADHD Results. Why Analysts Aren't Worried. ↗

March 25, 2025

The company is working on a non-stimulant approach to treating ADHD.

Via Investor's Business Daily

Axsome Therapeutics Lower Dose Of Attention Deficient Disorder Candidate Hits Primary Goal ↗

March 25, 2025

Axsome's solriamfetol met primary and key secondary endpoints in a Phase 3 ADHD trial, showing significant symptom reduction and a favorable safety profile.

Via Benzinga

Axsome Says Symbravo Hits Primary Goal In Late-Stage Migraine Trial In Patients Experiencing Inadequate Response To Commonly Used Drugs ↗

February 24, 2025

Axsome's Symbravo outperformed oral CGRP inhibitors in a Phase 3 trial, improving migraine pain relief, symptom control, and return to daily activities.

Via Benzinga

Axsome Therapeutics Stock Slips On Q4 Profit Miss, But Retail Takes It In Stride ↗

February 18, 2025

CEO Herriot Tabuteau struck an optimistic tone, citing strong commercial growth, a rapidly advancing pipeline, and the recent U.S. approval of Symbravo for migraine treatment.

Via Stocktwits

US, Russia Begin Ukrainian Peace Talks, Intel Shares Surge: What's Driving Markets Tuesday? ↗

February 18, 2025

Major U.S. indices are little-changed in Tuesday's midday trading as investors monitor recent geopolitical developments and anticipate the release of the latest FOMC minutes on Wednesday.

Via Benzinga

Axsome's AXS-05 In Alzheimer's Agitation Could Be Billion Dollar Opportunity, Says Analyst ↗

February 18, 2025

Axsome Therapeutics reports strong Q4 2024 revenues, driven by increased sales of Auvelity and Sunosi. Anticipated milestones and FDA approval for Symbravo make AXSM a top pick for 2025.

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9

...

17 18 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Axsome Therapeutics, Inc. - Common Stock (NQ:AXSM)

Headline News about Axsome Therapeutics, Inc. - Common Stock

Starting at $3.75/week.

Subscribe Today